Cipla gets USFDA nod for generic acid reflux drug

The company has received final approval for its abbreviated new drug
application (ANDA) for Esomeprazole for oral suspension in the
strengths of 10mg, 20mg and 40mg from the United States Food and Drug
Administration (USFDA), Cipla said in a statement.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-gets-usfda-nod-for-generic-acid-reflux-drug/articleshow/74824762.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment